info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Genome Editing Market Research Report Information By Technology (Meganucleases, (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Others), By Delivery Method (Ex-vivo, In-vivo), By Mode (Contract, In-house), By End-use (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations), By Application (Genetic Engineering, Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others), By Clinical Applications (Diagnostics, Therapy Development), And By Region (North America, Europ


ID: MRFR/HC/18755-HCR | 128 Pages | Author: Rahul Gotadki| November 2024

Genome Editing Market Segmentation


Genome editing Technology Outlook (USD Billion, 2018-2032)



  • Meganucleases

  • (CRISPR)/CAS9

  • TALENs/MegaTALs

  • ZFN

  • Others


Genome editing Delivery Method Outlook (USD Billion, 2018-2032)



  • Ex-vivo

  • In-vivo


Genome editing Mode Outlook (USD Billion, 2018-2032)



  • Contract

  • In-house


Genome editing End-use Outlook (USD Billion, 2018-2032)



  • Biotechnology & Pharmaceutical Companies

  • Academic & Government Research Institutes

  • Contract Research Organizations


Genome editing Application Outlook (USD Billion, 2018-2032)



  • Genetic Engineering

  • Cell Line Engineering

  • Animal Genetic Engineering

  • Plant Genetic Engineering

  • Others


Genome editing Clinical Applications Outlook (USD Billion, 2018-2032)



  • Diagnostics

  • Therapy Development


Genome editing Regional Outlook (USD Billion, 2018-2032)




  • North America Outlook (USD Billion, 2018-2032)


    • North America Genome editing by Technology

      • Meganucleases

      • (CRISPR)/CAS9

      • TALENs/MegaTALs

      • ZFN

      • Others




    • North America Genome editing by Delivery Method

      • Ex-vivo

      • In-vivo




    • North America Genome editing by Mode

      • Contract

      • In-house




    • North America Genome editing by End-use

      • Biotechnology & Pharmaceutical Companies

      • Academic & Government Research Institutes

      • Contract Research Organizations




    • North America Genome editing by Application

      • Genetic Engineering

      • Cell Line Engineering

      • Animal Genetic Engineering

      • Plant Genetic Engineering

      • Others




    • North America Genome editing by Clinical Applications

      • Diagnostics

      • Therapy Development




    • US Outlook (USD Billion, 2018-2032)


    • US Genome editing by Technology

      • Meganucleases

      • (CRISPR)/CAS9

      • TALENs/MegaTALs

      • ZFN

      • Others




    • US Genome editing by Delivery Method

      • Ex-vivo

      • In-vivo




    • US Genome editing by Mode

      • Contract

      • In-house




    • US Genome editing by End-use

      • Biotechnology & Pharmaceutical Companies

      • Academic & Government Research Institutes

      • Contract Research Organizations




    • US Genome editing by Application

      • Genetic Engineering

      • Cell Line Engineering

      • Animal Genetic Engineering

      • Plant Genetic Engineering

      • Others




    • US Genome editing by Clinical Applications

      • Diagnostics

      • Therapy Development




    • CANADA Outlook (USD Billion, 2018-2032)


    • CANADA Genome editing by Technology

      • Meganucleases

      • (CRISPR)/CAS9

      • TALENs/MegaTALs

      • ZFN

      • Others




    • CANADA Genome editing by Delivery Method

      • Ex-vivo

      • In-vivo




    • CANADA Genome editing by Mode

      • Contract

      • In-house




    • CANADA Genome editing by End-use

      • Biotechnology & Pharmaceutical Companies

      • Academic & Government Research Institutes

      • Contract Research Organizations




    • CANADA Genome editing by Application

      • Genetic Engineering

      • Cell Line Engineering

      • Animal Genetic Engineering

      • Plant Genetic Engineering

      • Others




    • CANADA Genome editing by Clinical Applications

      • Diagnostics

      • Therapy Development




    • Europe Outlook (USD Billion, 2018-2032)


      • Europe Genome editing by Technology

        • Meganucleases

        • (CRISPR)/CAS9

        • TALENs/MegaTALs

        • ZFN

        • Others




      • Europe Genome editing by Delivery Method

        • Ex-vivo

        • In-vivo




      • Europe Genome editing by Mode

        • Contract

        • In-house




      • Europe Genome editing by End-use

        • Biotechnology & Pharmaceutical Companies

        • Academic & Government Research Institutes

        • Contract Research Organizations




      • Europe Genome editing by Application

        • Genetic Engineering

        • Cell Line Engineering

        • Animal Genetic Engineering

        • Plant Genetic Engineering

        • Others




      • Europe Genome editing by Clinical Applications

        • Diagnostics

        • Therapy Development




      • Germany Outlook (USD Billion, 2018-2032)


      • Germany Genome editing by Technology

        • Meganucleases

        • (CRISPR)/CAS9

        • TALENs/MegaTALs

        • ZFN

        • Others




      • Germany Genome editing by Delivery Method

        • Ex-vivo

        • In-vivo




      • Germany Genome editing by Mode

        • Contract

        • In-house




      • Germany Genome editing by End-use

        • Biotechnology & Pharmaceutical Companies

        • Academic & Government Research Institutes

        • Contract Research Organizations




      • Germany Genome editing by Application

        • Genetic Engineering

        • Cell Line Engineering

        • Animal Genetic Engineering

        • Plant Genetic Engineering

        • Others




      • Germany Genome editing by Clinical Applications

        • Diagnostics

        • Therapy Development



      • France Outlook (USD Billion, 2018-2032)


      • France Genome editing by Technology

        • Meganucleases

        • (CRISPR)/CAS9

        • TALENs/MegaTALs

        • ZFN

        • Others




      • France Genome editing by Delivery Method

        • Ex-vivo

        • In-vivo




      • France Genome editing by Mode

        • Contract

        • In-house




      • France Genome editing by End-use

        • Biotechnology & Pharmaceutical Companies

        • Academic & Government Research Institutes

        • Contract Research Organizations




      • France Genome editing by Application

        • Genetic Engineering

        • Cell Line Engineering

        • Animal Genetic Engineering

        • Plant Genetic Engineering

        • Others




      • France Genome editing by Clinical Applications

        • Diagnostics

        • Therapy Development




      • UK Outlook (USD Billion, 2018-2032)


      • UK Genome editing by Technology

        • Meganucleases

        • (CRISPR)/CAS9

        • TALENs/MegaTALs

        • ZFN

        • Others




      • UK Genome editing by Delivery Method

        • Ex-vivo

        • In-vivo




      • UK Genome editing by Mode

        • Contract

        • In-house




      • UK Genome editing by End-use

        • Biotechnology & Pharmaceutical Companies

        • Academic & Government Research Institutes

        • Contract Research Organizations




      • UK Genome editing by Application

        • Genetic Engineering

        • Cell Line Engineering

        • Animal Genetic Engineering

        • Plant Genetic Engineering

        • Others




      • UK Genome editing by Clinical Applications

        • Diagnostics

        • Therapy Development




      • ITALY Outlook (USD Billion, 2018-2032)


      • ITALY Genome editing by Technology

        • Meganucleases

        • (CRISPR)/CAS9

        • TALENs/MegaTALs

        • ZFN

        • Others




      • ITALY Genome editing by Delivery Method

        • Ex-vivo

        • In-vivo




      • ITALY Genome editing by Mode

        • Contract

        • In-house




      • ITALY Genome editing by End-use

        • Biotechnology & Pharmaceutical Companies

        • Academic & Government Research Institutes

        • Contract Research Organizations




      • ITALY Genome editing by Application

        • Genetic Engineering

        • Cell Line Engineering

        • Animal Genetic Engineering

        • Plant Genetic Engineering

        • Others




      • ITALY Genome editing by Clinical Applications

        • Diagnostics

        • Therapy Development




      • SPAIN Outlook (USD Billion, 2018-2032)


      • Spain Genome editing by Technology

        • Meganucleases

        • (CRISPR)/CAS9

        • TALENs/MegaTALs

        • ZFN

        • Others




      • Spain Genome editing by Delivery Method

        • Ex-vivo

        • In-vivo




      • Spain Genome editing by Mode

        • Contract

        • In-house




      • Spain Genome editing by End-use

        • Biotechnology & Pharmaceutical Companies

        • Academic & Government Research Institutes

        • Contract Research Organizations




      • Spain Genome editing by Application

        • Genetic Engineering

        • Cell Line Engineering

        • Animal Genetic Engineering

        • Plant Genetic Engineering

        • Others




      • Spain Genome editing by Clinical Applications

        • Diagnostics

        • Therapy Development




      • Rest Of Europe Outlook (USD Billion, 2018-2032)


      • Rest Of Europe Genome editing by Technology

        • Meganucleases

        • (CRISPR)/CAS9

        • TALENs/MegaTALs

        • ZFN

        • Others




      • REST OF EUROPE Genome editing by Delivery Method

        • Ex-vivo

        • In-vivo




      • REST OF EUROPE Genome editing by Mode

        • Contract

        • In-house




      • REST OF EUROPE Genome editing by End-use

        • Biotechnology & Pharmaceutical Companies

        • Academic & Government Research Institutes

        • Contract Research Organizations




      • REST OF EUROPE Genome editing by Application

        • Genetic Engineering

        • Cell Line Engineering

        • Animal Genetic Engineering

        • Plant Genetic Engineering

        • Others




      • REST OF EUROPE Genome editing by Clinical Applications

        • Diagnostics

        • Therapy Development




      • Asia-Pacific Outlook (USD Billion, 2018-2032)


        • Asia-Pacific Genome editing by Technology

          • Meganucleases

          • (CRISPR)/CAS9

          • TALENs/MegaTALs

          • ZFN

          • Others




        • Asia-Pacific Genome editing by Delivery Method

          • Ex-vivo

          • In-vivo




        • Asia-Pacific Genome editing by Mode

          • Contract

          • In-house




        • Asia-Pacific Genome editing by End-use

          • Biotechnology & Pharmaceutical Companies

          • Academic & Government Research Institutes

          • Contract Research Organizations




        • Asia-Pacific Genome editing by Application

          • Genetic Engineering

          • Cell Line Engineering

          • Animal Genetic Engineering

          • Plant Genetic Engineering

          • Others




        • Asia-Pacific Genome editing by Clinical Applications

          • Diagnostics

          • Therapy Development




        • China Outlook (USD Billion, 2018-2032)


        • China Genome editing by Technology

          • Meganucleases

          • (CRISPR)/CAS9

          • TALENs/MegaTALs

          • ZFN

          • Others




        • China Genome editing by Delivery Method

          • Ex-vivo

          • In-vivo




        • China Genome editing by Mode

          • Contract

          • In-house




        • China Genome editing by End-use

          • Biotechnology & Pharmaceutical Companies

          • Academic & Government Research Institutes

          • Contract Research Organizations




        • China Genome editing by Application

          • Genetic Engineering

          • Cell Line Engineering

          • Animal Genetic Engineering

          • Plant Genetic Engineering

          • Others




        • China Genome editing by Clinical Applications

          • Diagnostics

          • Therapy Development




        • Japan Outlook (USD Billion, 2018-2032)


        • Japan Genome editing by Technology

          • Meganucleases

          • (CRISPR)/CAS9

          • TALENs/MegaTALs

          • ZFN

          • Others




        • Japan Genome editing by Delivery Method

          • Ex-vivo

          • In-vivo




        • Japan Genome editing by Mode

          • Contract

          • In-house




        • Japan Genome editing by End-use

          • Biotechnology & Pharmaceutical Companies

          • Academic & Government Research Institutes

          • Contract Research Organizations




        • Japan Genome editing by Application

          • Genetic Engineering

          • Cell Line Engineering

          • Animal Genetic Engineering

          • Plant Genetic Engineering

          • Others




        • Japan Genome editing by  Clinical Applications

          • Diagnostics

          • Therapy Development




        • India Outlook (USD Billion, 2018-2032)


        • India Genome editing by Technology

          • Meganucleases

          • (CRISPR)/CAS9

          • TALENs/MegaTALs

          • ZFN

          • Others




        • India Genome editing by Delivery Method

          • Ex-vivo

          • In-vivo




        • India Genome editing by Mode

          • Contract

          • In-house




        • India Genome editing by End-use

          • Biotechnology & Pharmaceutical Companies

          • Academic & Government Research Institutes

          • Contract Research Organizations




        • India Genome editing by Application

          • Genetic Engineering

          • Cell Line Engineering

          • Animal Genetic Engineering

          • Plant Genetic Engineering

          • Others




        • India Genome editing by Clinical Applications

          • Diagnostics

          • Therapy Development




        • Australia Outlook (USD Billion, 2018-2032)


        • Australia Genome editing by Technology

          • Meganucleases

          • (CRISPR)/CAS9

          • TALENs/MegaTALs

          • ZFN

          • Others




        • Australia Genome editing by Delivery Method

          • Ex-vivo

          • In-vivo




        • Australia Genome editing by Mode

          • Contract

          • In-house




        • Australia Genome editing by End-use

          • Biotechnology & Pharmaceutical Companies

          • Academic & Government Research Institutes

          • Contract Research Organizations




        • Australia Genome editing by Application

          • Genetic Engineering

          • Cell Line Engineering

          • Animal Genetic Engineering

          • Plant Genetic Engineering

          • Others




        • Australia Genome editing by Clinical Applications

          • Diagnostics

          • Therapy Development




        • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)


        • Rest of Asia-Pacific Genome editing by Technology

          • Meganucleases

          • (CRISPR)/CAS9

          • TALENs/MegaTALs

          • ZFN

          • Others




        • Rest of Asia-Pacific Genome editing by Delivery Method

          • Ex-vivo

          • In-vivo




        • Rest of Asia-Pacific Genome editing by Mode

          • Contract

          • In-house




        • Rest of Asia-Pacific Genome editing by End-use

          • Biotechnology & Pharmaceutical Companies

          • Academic & Government Research Institutes

          • Contract Research Organizations




        • Rest of Asia-Pacific Genome editing by Application

          • Genetic Engineering

          • Cell Line Engineering

          • Animal Genetic Engineering

          • Plant Genetic Engineering

          • Others




        • Rest of Asia-Pacific Genome editing by Clinical Applications

          • Diagnostics

          • Therapy Development




        • Rest of the World Outlook (USD Billion, 2018-2032)


          • Rest of the World Genome editing by Technology

            • Meganucleases

            • (CRISPR)/CAS9

            • TALENs/MegaTALs

            • ZFN

            • Others




          • Rest of the World Genome editing by Delivery Method

            • Ex-vivo

            • In-vivo




          • Rest of the World Genome editing by Mode

            • Contract

            • In-house




          • Rest of the World Genome editing by End-use

            • Biotechnology & Pharmaceutical Companies

            • Academic & Government Research Institutes

            • Contract Research Organizations




          • Rest of the World Genome editing by Application

            • Genetic Engineering

            • Cell Line Engineering

            • Animal Genetic Engineering

            • Plant Genetic Engineering

            • Others




          • Rest of the World Genome editing by Clinical Applications

            • Diagnostics

            • Therapy Development




          • Middle East Outlook (USD Billion, 2018-2032)


          • Middle East Genome editing by Technology

            • Meganucleases

            • (CRISPR)/CAS9

            • TALENs/MegaTALs

            • ZFN

            • Others




          • Middle East Genome editing by Delivery Method

            • Ex-vivo

            • In-vivo




          • Middle East Genome editing by Mode

            • Contract

            • In-house




          • Middle East Genome editing by End-use

            • Biotechnology & Pharmaceutical Companies

            • Academic & Government Research Institutes

            • Contract Research Organizations




          • Middle East Genome editing by Application

            • Genetic Engineering

            • Cell Line Engineering

            • Animal Genetic Engineering

            • Plant Genetic Engineering

            • Others




          • Middle East Genome editing by Clinical Applications

            • Diagnostics

            • Therapy Development




          • Africa Outlook (USD Billion, 2018-2032)


          • Africa Genome editing by Technology

            • Meganucleases

            • (CRISPR)/CAS9

            • TALENs/MegaTALs

            • ZFN

            • Others




          • Africa Genome editing by Delivery Method

            • Ex-vivo

            • In-vivo




          • Africa Genome editing by Mode

            • Contract

            • In-house




          • Africa Genome editing by End-use

            • Biotechnology & Pharmaceutical Companies

            • Academic & Government Research Institutes

            • Contract Research Organizations




          • Africa Genome editing by Application

            • Genetic Engineering

            • Cell Line Engineering

            • Animal Genetic Engineering

            • Plant Genetic Engineering

            • Others




          • Africa Genome editing by Clinical Applications

            • Diagnostics

            • Therapy Development




          • Latin America Outlook (USD Billion, 2018-2032)


          • Latin America Genome editing by Technology

            • Meganucleases

            • (CRISPR)/CAS9

            • TALENs/MegaTALs

            • ZFN

            • Others




          • Latin America Genome editing by Delivery Method

            • Ex-vivo

            • In-vivo




          • Latin America Genome editing by Mode

            • Contract

            • In-house




          • Latin America Genome editing by End-use

            • Biotechnology & Pharmaceutical Companies

            • Academic & Government Research Institutes

            • Contract Research Organizations




          • Latin America Genome editing by Application

            • Genetic Engineering

            • Cell Line Engineering

            • Animal Genetic Engineering

            • Plant Genetic Engineering

            • Others




          • Latin America Genome editing by Clinical Applications

            • Diagnostics

            • Therapy Development












 

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GENOME EDITING MARKET, BY TECHNOLOGY

6.1. Overview

6.2. Meganucleases

6.3. (CRISPR)/Cas9

6.4. TALENs/MegaTALs

6.5. ZFN

6.6. Others

7. GENOME EDITING MARKET, BY DELIVERY METHOD

7.1. Overview

7.2. Ex-vivo

7.3. In-vivo

8. GENOME EDITING MARKET, BY MODE

8.1. Overview

8.2. Contract

8.3. In-house

9. GENOME EDITING MARKET, BY END-USE

9.1. Overview

9.2. Biotechnology & Pharmaceutical Companies

9.3. Academic & Government Research Institutes

9.4. Contract Research Organizations

10. GENOME EDITING MARKET, BY APPLICATION

10.1. Overview

10.2. Genetic Engineering

10.3. Cell Line Engineering

10.4. Animal Genetic Engineering

10.5. Plant Genetic Engineering

10.6. Others

11. GENOME EDITING MARKET, BY CLINICAL APPLICATIONS

11.1. Overview

11.2. Diagnostics

11.3. Therapy Development

12. GENOME EDITING MARKET, BY REGION

12.1. Overview

12.1. North America

12.1.1. US

12.1.2. Canada

12.2. Europe

12.2.1. Germany

12.2.2. France

12.2.3. UK

12.2.4. Italy

12.2.5. Spain

12.2.6. Rest of Europe

12.3. Asia-Pacific

12.3.1. China

12.3.2. India

12.3.3. Japan

12.3.4. South Korea

12.3.5. Australia

12.3.6. Rest of Asia-Pacific

12.4. Rest of the World

12.4.1. Middle East

12.4.2. Africa

12.4.3. Latin America

13. COMPETITIVE LANDSCAPE

13.1. Overview

13.2. Competitive Analysis

13.3. Market Share Analysis

13.4. Major Growth Strategy in the Genome editing Market,

13.5. Competitive Benchmarking

13.6. Leading Players in Terms of Number of Developments in the Genome editing Market,

13.7. Key developments and Growth Strategies

13.7.1. New Product Launch/Service Deployment

13.7.2. Merger & Acquisitions

13.7.3. Joint Ventures

13.8. Major Players Financial Matrix

13.8.1. Sales & Operating Income, 2022

13.8.2. Major Players R&D Expenditure. 2022

14. COMPANY PROFILES

14.1. Merck KGaA

14.1.1. Company Overview

14.1.2. Financial Overview

14.1.3. Products Offered

14.1.4. Key Developments

14.1.5. SWOT Analysis

14.1.6. Key Strategies

14.2. Cibus

14.2.1. Company Overview

14.2.2. Financial Overview

14.2.3. Products Offered

14.2.4. Key Developments

14.2.5. SWOT Analysis

14.2.6. Key Strategies

14.3. Recombinetics, Inc.

14.3.1. Company Overview

14.3.2. Financial Overview

14.3.3. Products Offered

14.3.4. Key Developments

14.3.5. SWOT Analysis

14.3.6. Key Strategies

14.4. Sangamo

14.4.1. Company Overview

14.4.2. Financial Overview

14.4.3. Products Offered

14.4.4. Key Developments

14.4.5. SWOT Analysis

14.4.6. Key Strategies

14.5. Editas Medicine

14.5.1. Company Overview

14.5.2. Financial Overview

14.5.3. Products Offered

14.5.4. Key Developments

14.5.5. SWOT Analysis

14.5.6. Key Strategies

14.6. Precision Biosciences

14.6.1. Company Overview

14.6.2. Financial Overview

14.6.3. Products Offered

14.6.4. Key Developments

14.6.5. SWOT Analysis

14.6.6. Key Strategies

14.7. CRISPR Therapeutics

14.7.1. Company Overview

14.7.2. Financial Overview

14.7.3. Products Offered

14.7.4. Key Developments

14.7.5. SWOT Analysis

14.7.6. Key Strategies

14.8. Intellia Therapeutics, Inc.

14.8.1. Company Overview

14.8.2. Financial Overview

14.8.3. Products Offered

14.8.4. Key Developments

14.8.5. SWOT Analysis

14.8.6. Key Strategies

14.9. CARIBOU BIOSCIENCES, INC.

14.9.1. Company Overview

14.9.2. Financial Overview

14.9.3. Products Offered

14.9.4. Key Developments

14.9.5. SWOT Analysis

14.9.6. Key Strategies

14.10. Cellectis S.A.

14.10.1. Company Overview

14.10.2. Financial Overview

14.10.3. Products Offered

14.10.4. Key Developments

14.10.5. SWOT Analysis

14.10.6. Key Strategies

14.11. AstraZeneca

14.11.1. Company Overview

14.11.2. Financial Overview

14.11.3. Products Offered

14.11.4. Key Developments

14.11.5. SWOT Analysis

14.11.6. Key Strategies

14.12. Takara Bio USA

14.12.1. Company Overview

14.12.2. Financial Overview

14.12.3. Products Offered

14.12.4. Key Developments

14.12.5. SWOT Analysis

14.12.6. Key Strategies

14.13. Horizon Discovery Group plc

14.13.1. Company Overview

14.13.2. Financial Overview

14.13.3. Products Offered

14.13.4. Key Developments

14.13.5. SWOT Analysis

14.13.6. Key Strategies

15. APPENDIX

15.1. References

15.2. Related Reports

LIST OF TABLES

TABLE 1 GENOME EDITING MARKET, SYNOPSIS, 2018-2032

TABLE 2 GENOME EDITING MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)

TABLE 3 GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 4 GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 5 GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 6 GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 7 GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 8 GENOME EDITING MARKET, BY CLINICAL APPLICATIONS , 2018-2032 (USD BILLION)

TABLE 9 NORTH AMERICA: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 10 NORTH AMERICA: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 11 NORTH AMERICA: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 12 NORTH AMERICA: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 13 NORTH AMERICA: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 14 NORTH AMERICA: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 15 US: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 16 US: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 17 US: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 18 US: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 19 US: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 20 US: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 21 CANADA: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 22 CANADA: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 23 CANADA: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 24 CANADA: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 25 CANADA: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 26 CANADA: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 1 EUROPE: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 2 EUROPE: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 3 EUROPE: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 4 EUROPE: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 5 EUROPE: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 6 EUROPE: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 7 GERMANY: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 8 GERMANY: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 9 GERMANY: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 10 GERMANY: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 11 GERMANY: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 12 GERMANY: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 13 FRANCE: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 14 FRANCE: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 15 FRANCE: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 16 FRANCE: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 17 FRANCE: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 18 FRANCE: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 19 ITALY: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 20 ITALY: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 21 ITALY: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 22 ITALY: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 23 ITALY: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 24 ITALY: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 25 SPAIN: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 26 SPAIN: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 27 SPAIN: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 28 SPAIN: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 29 SPAIN: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 30 SPAIN: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 31 UK: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 32 UK: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 33 UK: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 34 UK: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 35 UK: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 36 UK: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 37 REST OF EUROPE: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 38 REST OF EUROPE: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 39 REST OF EUROPE: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 40 REST OF EUROPE: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 41 REST OF EUROPE: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 42 REST OF EUROPE: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 43 ASIA-PACIFIC: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 44 ASIA-PACIFIC: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 45 ASIA-PACIFIC: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 46 ASIA-PACIFIC: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 47 ASIA-PACIFIC: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 48 ASIA-PACIFIC: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 49 JAPAN: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 50 JAPAN: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 51 JAPAN: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 52 JAPAN: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 53 JAPAN: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 54 JAPAN: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 55 CHINA: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 56 CHINA: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 57 CHINA: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 58 CHINA: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 59 CHINA: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 60 CHINA: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 61 INDIA: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 62 INDIA: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 63 INDIA: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 64 INDIA: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 65 INDIA: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 66 INDIA: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 67 AUSTRALIA: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 68 AUSTRALIA: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 69 AUSTRALIA: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 70 AUSTRALIA: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 71 AUSTRALIA: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 72 AUSTRALIA: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 73 SOUTH KOREA: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 74 SOUTH KOREA: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 75 SOUTH KOREA: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 76 SOUTH KOREA: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 77 SOUTH KOREA: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 78 SOUTH KOREA: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 79 REST OF ASIA-PACIFIC: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 80 REST OF ASIA-PACIFIC: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 81 REST OF ASIA-PACIFIC: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 82 REST OF ASIA-PACIFIC: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 83 REST OF ASIA-PACIFIC: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 84 REST OF ASIA-PACIFIC: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 85 REST OF THE WORLD: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 86 REST OF THE WORLD: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 87 REST OF THE WORLD: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 88 REST OF THE WORLD: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 89 REST OF THE WORLD: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 90 REST OF THE WORLD: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 91 MIDDLE EAST: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 92 MIDDLE EAST: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 93 MIDDLE EAST: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 94 MIDDLE EAST: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 95 MIDDLE EAST: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 96 MIDDLE EAST: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 97 AFRICA: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 98 AFRICA: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 99 AFRICA: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 100 AFRICA: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 101 AFRICA: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 102 AFRICA: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

TABLE 103 LATIN AMERICA: GENOME EDITING MARKET, BY TECHNOLOGY , 2018-2032 (USD BILLION)

TABLE 104 LATIN AMERICA: GENOME EDITING MARKET, BY DELIVERY METHOD , 2018-2032 (USD BILLION)

TABLE 105 LATIN AMERICA: GENOME EDITING MARKET, BY MODE, 2018-2032 (USD BILLION)

TABLE 106 LATIN AMERICA: GENOME EDITING MARKET, BY END-USE , 2018-2032 (USD BILLION)

TABLE 107 LATIN AMERICA: GENOME EDITING MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 108 LATIN AMERICA: GENOME EDITING MARKET, BY CLINICAL APPLICATIONS, 2018-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GENOME EDITING MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GENOME EDITING MARKET

FIGURE 4 GENOME EDITING MARKET, SHARE (%), BY TECHNOLOGY , 2022

FIGURE 5 GENOME EDITING MARKET, SHARE (%), BY DELIVERY METHOD , 2022

FIGURE 6 GENOME EDITING MARKET, SHARE (%), BY MODE, 2022

FIGURE 7 GENOME EDITING MARKET, SHARE (%), BY END-USE , 2022

FIGURE 8 GENOME EDITING MARKET, SHARE (%), BY APPLICATION, 2022

FIGURE 9 GENOME EDITING MARKET, SHARE (%), BY CLINICAL APPLICATIONS, 2022

FIGURE 10 GENOME EDITING MARKET, SHARE (%), BY REGION, 2022

FIGURE 11 NORTH AMERICA: GENOME EDITING MARKET, SHARE (%), BY REGION, 2022

FIGURE 12 EUROPE: GENOME EDITING MARKET, SHARE (%), BY REGION, 2022

FIGURE 13 ASIA-PACIFIC: GENOME EDITING MARKET, SHARE (%), BY REGION, 2022

FIGURE 14 REST OF THE WORLD: GENOME EDITING MARKET, SHARE (%), BY REGION, 2022

FIGURE 15 GENOME EDITING MARKET: COMPANY SHARE ANALYSIS, 2022 (%)

FIGURE 16 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 MERCK KGAA: SWOT ANALYSIS

FIGURE 18 CIBUS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 CIBUS: SWOT ANALYSIS

FIGURE 20 RECOMBINETICS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 RECOMBINETICS, INC.: SWOT ANALYSIS

FIGURE 22 SANGAMO: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 SANGAMO: SWOT ANALYSIS

FIGURE 24 EDITAS MEDICINE: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 EDITAS MEDICINE: SWOT ANALYSIS

FIGURE 26 PRECISION BIOSCIENCES.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 PRECISION BIOSCIENCES.: SWOT ANALYSIS

FIGURE 28 CRISPR THERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 CRISPR THERAPEUTICS: SWOT ANALYSIS

FIGURE 30 INTELLIA THERAPEUTICS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 INTELLIA THERAPEUTICS, INC.: SWOT ANALYSIS

FIGURE 32 CARIBOU BIOSCIENCES, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 CARIBOU BIOSCIENCES, INC.: SWOT ANALYSIS

FIGURE 34 CELLECTIS S.A.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 CELLECTIS S.A.: SWOT ANALYSIS

FIGURE 36 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 ASTRAZENECA: SWOT ANALYSIS

FIGURE 38 TAKARA BIO USA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 39 TAKARA BIO USA: SWOT ANALYSIS

FIGURE 40 HORIZON DISCOVERY GROUP PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 41 HORIZON DISCOVERY GROUP PLC: SWOT ANALYSIS

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.